- Conditions
- Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab
- Drug · Combination Product
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 57
- States / cities
- Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Skin Aging
- Interventions
- Investigational Facial Serum #1, Investigational Facial Serum #2, Investigational Facial Serum #3
- Other
- Lead sponsor
- Victoria Collotta
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Needham, Massachusetts
- Conditions
- Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
- Interventions
- Temozolomide, Bevacizumab, Irinotecan
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 30 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cincinnati, Ohio
- Conditions
- Cannabis Smoking, Oxidative Stress
- Interventions
- Bronchoscopy, Chest X-ray, Venipuncture, Intravenous Catheter
- Procedure · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Pembrolizumab, Doxorubicin, Vinblastine, Dacarbazine, Brentuximab vedotin
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Philadelphia, Pennsylvania • Charlottesville, Virginia
- Conditions
- Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies, Inborn Errors of Metabolism, Sickle Cell, Thalassemia, Lysosomal Storage Disease
- Interventions
- Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
- Biological · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- IBI-20089/Lucentis
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lung Diseases, Interstitial, Pulmonary Fibrosis
- Interventions
- CT-V, Metabolites
- Device · Other
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Metastatic Breast Cancer
- Interventions
- Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoproliferative Disorder
- Interventions
- rituximab, cyclophosphamide, methylprednisolone, prednisone
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- Anemia, Unexplained Anemia (UAE)
- Interventions
- iron sucrose
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Cleveland, Ohio + 1 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- AAV8 DetectCDx
- Diagnostic Test
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 0 Years to 25 Years · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pompe Disease
- Interventions
- Rituximab, Miglustat
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Wound Healing, Burns
- Interventions
- Healthy volunteers, Burn volunteers
- Genetic · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 14 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Dexamethasone, Vincristine, Inotuzumab, Blinatumomab, Dasatinib, IT MHA, Cyclophosphamide, Cytarabine, Methotrexate, 6-Mercaptopurine, Calaspargase, Daunorubicin, Thioguanine
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee
- Conditions
- Hodgkin Lymphoma
- Interventions
- doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 9
- States / cities
- Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Placebo, Etanercept
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node
- Interventions
- Sample Collection
- Other
- Lead sponsor
- Castleman Disease Collaborative Network
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Efalizumab, Abatacept, Belatacept
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Choroidal Neovascularization
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Vision Research Foundation
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Lymphoma, Large-Cell, Diffuse
- Interventions
- Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
- Drug · Procedure
- Lead sponsor
- Lymphoma Study Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, carboplatin, pemetrexed disodium
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 70 Years to 120 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 217
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 140 more
- Conditions
- Age-Related Maculopathy, Choroidal Neovascularization
- Interventions
- Ranibizumab, Verteporfin
- Drug
- Lead sponsor
- Oklahoma State University Center for Health Sciences
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Metastatic Melanoma
- Interventions
- Nivolumab, Pembrolizumab, Dabrafenib+Trametinib, Ipilimumab+Nivolumab, Vemurafenib+Cobimetinib, Encorafenib+Binimetinib
- Drug · Combination Product
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey